Tuesday, July 29, 2014

Kentucky Tobacco Smokes Out An Ebola Treatment; Phase 1 Clinical Trials Contracting Now

Update 8/4
Adding Ebola infected bodily fluids to an ultrasonic humidifier is close to all it takes to weaponize Ebola into a bioweapon of mass infection


The Defense Threat Reduction Agency (DTRA) is giving MAPP Biopharmaceutical a sole source cost plus contract to produce ZMapp™, an Ebola Zaire monoclonal antibody cocktail for use in a DTRA's phase one Ebola treament clinical trials.

 ZMapp™ is a compromised of LeafBio's proprietary Ebola-specific antibody drug MB-003 combined with Defyrus’ ZMAb antibody portfolio.  ZMapp is being harvested in Owensboro Kentucky from antibodies produced by flowering tobacco plants (Nicotiana).

Whether this treatment course will be made available to the American missionary team which has contracted Ebola is unknown.


MB-2003: An Ebola Virus Countermeasure     Solicitation Number: HDTRA1-13-C-0018-P00003


  1. Since Ebola is not new why did they wait so long? I wouldn't trust any of these maniacs.

    1. Government funding by crisis real or perceived